Intra-Cellular Therapies
ITCI
#1806
Rank
$9.13 B
Marketcap
$86.17
Share price
-0.43%
Change (1 day)
53.85%
Change (1 year)

Operating Margin for Intra-Cellular Therapies (ITCI)

Operating Margin as of November 2024 (TTM): -14.80%

According to Intra-Cellular Therapies's latest financial reports and stock price the company's current Operating Margin is -14.80%. At the end of 2023 the company had an Operating Margin of -34.48%.

Operating Margin history for Intra-Cellular Therapies from 2014 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
2023-34.48%-67.41%
2022-105.82%-69.74%
2021-349.65%-65.93%
2020-1,026.27%
2017-41,732.65%19.67%
2016-34,872.43%-89.8%
2015-341,797.00%5999.5%
2014-5,603.69%484.56%
2013-958.61%82.65%
2012-524.84%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
-856.84% 5,689.46%๐Ÿ‡บ๐Ÿ‡ธ USA
-473.04% 3,096.22%๐Ÿ‡บ๐Ÿ‡ธ USA
-130.01% 778.45%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.